Inhibition of epidermal growth factor receptor (EGFR) signaling has been suggested as a therapeutic strategy for several types of cancer with high mortality rates, including non-small cell lung cancer (NSCLC) [1, 2]. Here, EGFR is linked to non-small cell lung carcinoma.